Protalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see sustainable profitability on the horizon.
Strong revenue growth from its flagship Fabry disease treatment, Elfabrio, and a robust pipeline have prompted price target increases, with HC Wainwright raising its outlook to $15 per share and Zacks maintaining a valuation of $14.
Elfabrio, a PEGylated enzyme replacement therapy for Fabry disease, continues to gain traction globally under commercialization partner Chiesi Global Rare Diseases.
Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, which leads to a deficiency of an enzyme called alpha-galactosidase A. This enzyme is responsible for breaking down a type of fat called globotriaosylceramide (GL-3 or Gb3). Without enough of this enzyme, GL-3 accumulates in cells, particularly in the blood vessels, kidneys, heart, and nervous system, causing progressive damage.
HC Wainwright noted that Protalix reported a 75% year-over-year increase in third-quarter revenue, reaching $17.8 million.
“Protalix may achieve sustainable profitability from this year forward, driven mainly by the Elfabrio royalty stream,” HC Wainwright wrote.
Zacks highlighted Elfabrio’s competitive advantages over existing treatments, emphasizing that it stays in the bloodstream longer and may cause fewer immune reactions compared to Fabrazyme and Replagal. “This creates a wide opening for Elfabrio to step in and take market share in the underserved Fabry population,” Zacks wrote.
An application for Elfabrio is pending before the European Medicines Agency (EMA) to extend its dosing regimen to once every four weeks instead of every two. If approved, analysts believe this could significantly improve patient convenience and differentiate Elfabrio from competitors.
Pipeline progress
Beyond its commercialized portfolio, Protalix is advancing PRX-115, a recombinant PEGylated uricase targeting uncontrolled gout. HC Wainwright called it a “risk-mitigated, possibly underrated future contributor” and pointed to promising Phase 1 results showing dose-dependent reductions in plasma uric acid levels lasting up to 12 weeks.
A Phase 2 trial is expected in the second half of 2025.
Protalix’s financial position is another bright spot. The company has eliminated all debt and holds over $27 million in cash. Zacks underscored that “one of the primary risks in the small cap space is absent for Protalix, which is the need to raise capital and dilute earlier investors.”
Bullish sentiment
As Protalix advances its growth strategy, analysts see continued upside potential, particularly if Elfabrio’s market share expands and pipeline assets progress smoothly through clinical trials.
HC Wainwright’s price target increase from $10 to $15 reflects the firm’s belief that “sustainable profitability looks achievable,” thanks to Protalix’s growing revenue stream and strong balance sheet.
Meanwhile, Zacks maintains its $14 valuation, citing the company’s “enviable position in the small cap biotech space” with two approved products and a promising development pipeline.